On Monday, Shares of Mallinckrodt PLC (NYSE:MNK), gained 0.49% to $57.22.
Mallinckrodt plc, declared that the U.S. Food and Drug Administration (FDA) has cleared INOmax DSIR Plus MRI device for delivery of INOMAX® (nitric oxide) for inhalation during MRI procedures.
The INOmax DSIR Plus MRI delivery system is indicated for delivery of INOMAX (nitric oxide) for inhalation therapy gas into the patient-breathing circuit to provide a constant concentration of nitric oxide (NO) to the patient. The INOmax DSIR Plus MRI is indicated for use only with Magnetic Resonance Conditional ventilators validated to be compatible, as identified in the device labeling.
“Neonates being treated with INOmax frequently have multiple medical concerns that may need diagnostic imaging, such as an MRI scan, to guide medical administration. Before INOmax DSIR Plus MRI, physicians had to make the difficult decision to take the risk of interrupting INOmax treatment so that imaging could be done,” said Dr. Stephen Welty, Professor of Pediatrics and leading neonatologist. “Now, we can deliver uninterrupted inhaled nitric oxide treatment during diagnostic imaging, which will facilitate clinical decision-making and patient care.”
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, counting neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the administration of spasticity of cerebral.
Shares of Computer Sciences Corporation (NYSE:CSC), inclined 6.13% to $68.77, during its last trading session.
Computer Sciences Corporation, confirmed that it has sent a letter to Xchanging plc (“Xchanging”)’s board outlining its interest in making an offer to acquire the entire issued and to be issued share capital of Xchanging by way of an all cash offer of 170 pence per share.
CSC’s proposal represents a premium of over 6 percent to Capita plc’s recommended all cash final offer of 160 pence per share declared on 14 October 2015.
Xchanging shareholders who have not already accepted Capita’s offer for Xchanging declared on 14 October 2015 are urged not to accept Capita’s offer. CSC will make a further declarement in due course.
CSC reserves the right to reduce the offer consideration by the amount of any dividend (or other distribution) which is paid or becomes payable by Xchanging to its shareholders after the date of this declarement.
Computer Sciences Corporation provides information technology (IT) and professional services and solutions primarily in North America, Europe, Asia, and Australia. The company operates through Global Business Services, Global Infrastructure Services, and North American Public Sector segments.
Finally, Shares of Illumina, Inc. (NASDAQ:ILMN), ended its last trade with 2.69% gain, and closed at $170.11.
Working Opportunity Fund, declares a $7.5 million cash dividend under the Cash Dividend Distribution Policy adopted for the Fund’s Venture Series with an effective date of December 1, 2015 and provides a portfolio update. The $7.5 million cash dividend represents about 5% of Venture Series pricing net asset value.
As formerly stated, the Fund adopted a cash dividend distribution policy for the Venture Series to distribute available cash through an orderly realization of value from dispositions in the Venture Series portfolio while maintaining funds for planned follow-on investments, liabilities and anticipated operating expenses of the Venture Series. In declaring the dividend, the Board assessed the amount of funds received from exits in the venture portfolio for 2015 in light of potential follow-on investments in the portfolio and operating expenses.
We are happy to report that several portfolio companies continued to make good progress advancing their technologies and relationships with partners in 2015. One of Venture Series portfolio companies, Burnaby -based General Fusion, was profiled for the cover feature of the November 2, 2015 issue of Time magazine.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis.